Can hormone help treat multiple sclerosis long-term?

A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013.

The study involved 23 people with MS who were taking beta-interferon and had at least one relapse or brain scan showing new disease activity within the previous year. They were considered to have "breakthrough" MS, which means that their treatment that had been working previously stopped being effective, leading to worsening disability and more frequent relapses, as well as increased evidence of disease activity on brain scans.

The were given either ACTH or as pulse therapy monthly in addition to their regular treatment for one year. The people with MS knew which treatment they were receiving, but the researchers examining them did not.

The participants were tested every three months for 15 months. Over that time, those receiving ACTH had fewer relapses, or 0.08 cumulative relapses per patient compared to 0.8 relapses per patient for those receiving methylprednisolone. Those taking ACTH also had no cases of psychiatric side effects, while those taking methylprednisolone had a cumulative number of 0.55 psychiatric episodes per patient.

"These results are of interest because few treatments are available for people with breakthrough MS," said study author Regina Berkovich, MD, PhD, of Keck Medical Center of USC in Los Angeles. "Further studies, including randomized controlled trials, are needed to validate these preliminary findings, but the results suggest a potential benefit of ACTH pulse therapy in breakthrough MS."

While ACTH has been approved for use in MS relapses for many years, its cost has limited its use to only those patients who are in need of a treatment alternative to . This is believed to be the first study to have been done on its use as a chronic treatment for MS. ACTH is not FDA-approved for use as chronic treatment for MS.

add to favorites email to friend print save as pdf

Related Stories

High dietary salt may worsen multiple sclerosis symptoms

9 hours ago

High dietary salt intake may worsen multiple sclerosis symptoms and boost the risk of further neurological deterioration, indicates a small observational study published online in the Journal of Neurology, Ne ...

FDA approves Biogen's MS drug Plegridy

Aug 16, 2014

Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.

Dimethyl fumarate for MS: Added benefit is not proven

Aug 07, 2014

Dimethyl fumarate (trade name: Tecfidera) has been approved since January 2014 for adults with relapsing remitting multiple sclerosis (RRMS). In an early benefit assessment pursuant to the Act on the Reform of the Market ...

Miriam Hospital study examines smoking prevalence

Jul 11, 2014

Researchers from The Miriam Hospital have found that people with mobility impairments under age 65 have significantly higher rates of smoking than those without mobility impairments. Additionally, smokers with mobility impairments ...

Recommended for you

Why your favourite song takes you down memory lane

13 hours ago

Music triggers different functions of the brain, which helps explain why listening to a song you like might be enjoyable but a favourite song may plunge you into nostalgia, scientists said on Thursday.

Transcranial Magnetic Stimulation of brain boosts memory

14 hours ago

Stimulating a particular region in the brain via non-invasive delivery of electrical current using magnetic pulses, called Transcranial Magnetic Stimulation, improves memory, reports a new Northwestern Medicine ...

User comments